Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders
-
- Junichi Yamamoto
- School of Life Science and Technology, Tokyo Institute of Technology, Yokohama 226-8501, Japan
-
- Takumi Ito
- Institute of Medical Science, Tokyo Medical University, Shinjuku, Tokyo 160-8402, Japan
-
- Yuki Yamaguchi
- School of Life Science and Technology, Tokyo Institute of Technology, Yokohama 226-8501, Japan
-
- Hiroshi Handa
- Center for Future Medical Research, Tokyo Medical University, Shinjuku, Tokyo 160-8402, Japan
説明
<jats:p>Thalidomide and its derivatives are the only protein degraders currently used in clinical practice. This tutorial review provides an overview of the mechanism of action of thalidomide-based degraders and their future perspectives.</jats:p>
収録刊行物
-
- Chemical Society Reviews
-
Chemical Society Reviews 51 (15), 6234-6250, 2022
Royal Society of Chemistry (RSC)
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1360861707358996480
-
- ISSN
- 14604744
- 03060012
-
- データソース種別
-
- Crossref
- KAKEN